ArticleMetabolic brain disease2025
Promotion of angiogenesis in cerebral infarction by Tongqiao Huoxue Decoction through activation of glycolysis.
Article in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- HIF-1α in ischemic stroke: context-dependent roles in ferroptosis and neurovascular repair.Frontiers in neurology · 2026Review
- Hypoxia-inducible factor 1-alpha: a dual regulator of ferroptosis in ischemic stroke and a promising therapeutic target.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Angiogenesis plays a critical role in mitigating cerebral infarction injury. However, both endogenous and exogenous angiogenic responses are often insufficient to generate stable, functional blood vessels. Brain microvascular endothelial cells rely primarily on glycolysis for energy, a process that intensifies under hypoxic conditions. Therefore, enhancing energy metabolism may support angiogenesis. Tongqiao Huoxue Decoction (TQHXD) has been shown to have therapeutic effects on cerebral infarction, but its ability to promote angiogenesis by enhancing glycolysis remains unclear. We established an in vivo middle cerebral artery occlusion (MCAO) model and analyzed four postinfarction stages: hyperacute, acute, subacute and chronic. Brain injury in MCAO rats was assessed using neurobehavioral scoring, 2,3,5-triphenyltetrazolium chloride (TTC) staining, hematoxylin‒eosin (HE) staining, and brain water content measurements. The relationship between angiogenesis and glycolysis was further evaluated using enzyme-linked immunosorbent assays (ELISAs), western blotting (WB), reverse transcription polymerase chain reaction (RT‒PCR), and immunohistochemistry (IHC). TQHXD significantly alleviated brain injury and improved neurological function in MCAO rats. Treatment with TQHXD markedly increased the expressions of hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF), which are potentially linked to elevated levels of glucose, pyruvate, lactate, glucose transporter 1 (GLUT1), phosphofructokinase (PFK), and lactate dehydrogenase A (LDHA). Therefore, in the early stages of cerebral infarction (hyperacute and acute stages), TQHXD activates the HIF-1α/VEGF pathway by enhancing glycolysis, thereby accelerating the formation of new blood vessels and inhibiting cerebral infarction damage.
Indexed as
Identifiers
41074933What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.